Neurocrine Biosciences Inc at Piper Sandler Healthcare Conference Transcript
Okay. We are live. Well, let's kick things off. This is David Amsellem from the Piper Sandler biopharma research team. We're delighted to have Neurocrine here. We have Matt Abernethy, CFO. We have Eric Benevich, Chief Commercial Officer. We have Todd Tushla, Director of Investor Relations. Thanks, gentlemen, for joining us.
So it's been quite a year. So I would love to turn it over to Matt for just a few opening remarks on, I guess, a reflection on what's been to say the least, an interesting year, both for Neurocrine and for the biotech space, we're at large.
Well, I like how you said delighted to have us here. I think this year, anybody who thinks it's been a delight, I think, is fooling themselves. I was talking to investor before this, and they were reflecting on we're sitting here in a really good space -- spot from a stock performance, but getting here, man, it's been a slog, I think, for the entire industry. So I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
